Park Sang-Won, Durkin Marian E, Thorgeirsson Snorri S, Popescu Nicholas C
Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute/NIH, 37 Convent Drive, Bethesda, MD 20892, USA.
Int J Oncol. 2003 Jul;23(1):133-7.
The DLC-1 gene encoding a regulator of the Rho family of small GTPases is altered in breast, prostate, colon, and liver cancer and has several characteristics of a tumor suppressor gene. DLC-1 overexpression causes inhibition of in vitro growth of liver tumor cells and complete suppression of in vivo tumorigenicity of breast tumor cells. Inactivation and aberrant expression of DLC-1 in human hepatocellular carcinoma (HCC) is frequently associated with hemizygous and homozygous genomic deletion and promoter methylation. Since inactivation of tumor suppressor genes in cancer cells is also commonly associated with point mutation, we evaluated the incidence of mutation of the DLC-1 gene by PCR-SSCP in 17 primary HCC and 18 HCC cell lines. One missense mutation was detected at codon 991 of exon 12 (C-->T transition, Val-->Ile) in an HCC cell line. In addition, two types of polymorphisms were identified: a G-->T at codon 745 of exon 9, a T-->C at 17 bp downstream of exon 2. While the pathogenic relevance of the intronic polymorphism is not known, the low rate of mutation of the DLC-1 gene in HCC implies that genomic deletion and promoter methylation primarily account for the altered expression and tumor suppressive inactivation of the DLC-1 gene.
编码小GTP酶Rho家族调节剂的DLC-1基因在乳腺癌、前列腺癌、结肠癌和肝癌中发生改变,具有肿瘤抑制基因的多个特征。DLC-1的过表达会抑制肝肿瘤细胞的体外生长,并完全抑制乳腺肿瘤细胞的体内致瘤性。在人类肝细胞癌(HCC)中,DLC-1的失活和异常表达常与半合子和纯合子基因组缺失及启动子甲基化相关。由于癌细胞中肿瘤抑制基因的失活也通常与点突变有关,我们通过PCR-SSCP评估了17例原发性HCC和18种HCC细胞系中DLC-1基因的突变发生率。在一种HCC细胞系的第12外显子密码子991处检测到一个错义突变(C→T转换,Val→Ile)。此外,还鉴定出两种多态性:第9外显子密码子745处的G→T,第2外显子下游17 bp处的T→C。虽然内含子多态性的致病相关性尚不清楚,但HCC中DLC-1基因的低突变率表明基因组缺失和启动子甲基化主要导致了DLC-1基因表达改变和肿瘤抑制失活。